Latest News


Each news article below shows only part of the news story. To view the full story, click on Read More below the story. 

  • December 11, 2018 8:31 AM | Anonymous

    December 11, 2018, MedPage Today  

    Results of the 30-year prospective University of Kentucky Ovarian Cancer Screening Trial are adding to a body of evidence suggesting that an annual transvaginal ultrasound can detect early-stage ovarian cancer and improve survival rates for this patient population.

    Read more.

  • December 11, 2018 8:27 AM | Anonymous

    December 11, 2018, MedPage Today  

    Women's risk of breast cancer was highest about 5 years after childbirth, and lasted more than 20 years, compared with women who have never given birth, and breastfeeding did not appear to attenuate the risk, a large pooled analysis found. 

    Read more.

  • December 07, 2018 8:32 AM | Anonymous
    December 7, 2018, MedPage Today  


    Obesity may diminish survival in women with CLL who undergo chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR), a study from Germany found. 

    Read more.

  • December 06, 2018 8:24 AM | Anonymous
    December 6, 2018, Monthly Prescribing Reference b 


    Menopausal hormone therapy appears to reduce the risk of carpal tunnel syndrome in postmenopausal women, according to a study published in Plos One. To investigate the association between hormone therapy and carpal tunnel syndrome risk, researchers conducted a secondary analysis of the Women's Health Initiative (WHI) hormone therapy trials.  

    Read more.


  • December 06, 2018 8:21 AM | Anonymous
    December 6, 2018, HemOnc Today 


    Adjuvant ado-trastuzumab emtansine reduced risk for invasive recurrence by 50 percent compared with trastuzumab among patients with HER2-positive early breast cancer who still had residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy, according to results of the KATHERINE trial presented at San Antonio Breast Cancer Symposium. 

    Read more.

  • December 05, 2018 10:54 AM | Anonymous

    APAOG Annual Meeting Sponsorship Opportunities

    Consider sponsoring the APAOG Reception at the 2019 AAPA Annual Conference in Denver, CO!

    Event Details:

    Sunday, May 19th
    Time : TBD (evening) 
    Location: TBD 
    Denver, CO

    Sponsorship Details:

    • $5,000 Exclusive Sponsor 
    • $2,500 Partner Sponsor
    • $1,000 Affiliate Sponsor

    Exclusive Sponsor - 1 at $5,000 

    Includes Partner and Affiliate benefits listed below, as well as dedicated time to present at the event.

    Partner Sponsor - 1 at  $2,500

    Includes all Affiliate benefits below and:

    • Recognition on the website and all event promotion
    • Opportunity to place materials at APAOG Exhibit Booth at AAPA.
    • One quarter of advertising on APAOG website

    Affiliate Sponsor - 1 at $1,000

    Affiliate Sponsor Package Includes:

    • 2019 Affiliate APAOG Membership
    • Recognition on Welcome Signs at Event
    • Logo included on Email invitation to attendees. 

    Learn more here.


  • November 30, 2018 8:15 AM | Anonymous

    November 30, 2018, National Institutes of Health via Medical Xpress  

    NIBIB-funded researchers recently validated a rapid STD test that delivered accurate results in about 30 minutes for chlamydia, allowing patients to receive treatment immediately, thereby stemming the further spread of disease. Other analyses showed most women preferred the easy self-collection method the test offers.

    Read more. 

  • November 29, 2018 9:32 AM | Anonymous

    November 29, 2018, MedPage Today   

    While prenatal ultrasound imaging detected fetal abnormalities among most infants with intrauterine exposure to Zika virus, a few had abnormalities that were only seen during postnatal imaging, researchers found. 

    Read more.

  • November 29, 2018 9:28 AM | Anonymous

    November 29, 2018, Medscape  

    A novel test engineered from a bacterial toxin has been shown to detect significant levels of a specific biomarker released into the blood by ovarian cancer cells at all stages of the disease, including the early stages, distinguishing patients with ovarian cancer from healthy unaffected controls, research indicates. 

    Read more.

  • November 27, 2018 3:54 PM | Anonymous

    November 27, 2018, MedPage Today 

    Clinicians should offer pre-exposure prophylaxis (PrEP) with antiretroviral therapy to patients at high risk for HIV infection, the U.S. Preventive Services Task Force (USPSTF) said. For the first time, the USPSTF reviewed the topic and determined that, when taken as prescribed, PrEP is highly effective at preventing HIV among those at high risk, and concluded with "high certainty" that there is a "substantial benefit" to use in this population ("A" recommendation). 

    Read more.

Powered by Wild Apricot Membership Software